These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 26233226)
1. Erratum: "Three-dimensional texture analysis of contrast enhanced CT images for treatment response assessment in Hodgkin lymphoma: Comparison with F-18-FDG PET" [Med. Phys. 41(12), 121904 (2014)]. Knogler T; El-Rabadi K; Weber M; Karanikas G; Mayerhoefer ME Med Phys; 2015 Aug; 42(8):4998. PubMed ID: 26233226 [No Abstract] [Full Text] [Related]
2. Three-dimensional texture analysis of contrast enhanced CT images for treatment response assessment in Hodgkin lymphoma: comparison with F-18-FDG PET. Knogler T; El-Rabadi K; Weber M; Karanikas G; Mayerhoefer ME Med Phys; 2014 Dec; 41(12):121904. PubMed ID: 25471964 [TBL] [Abstract][Full Text] [Related]
3. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions. Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients. Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598 [TBL] [Abstract][Full Text] [Related]
5. [Comparison of ¹⁸F-FDG PET/CT and large-scale DWI for evaluation of non-Hodgkin lymphoma bone marrow infiltration]. Tang R; Gui S; Li J; Zhang H; Lu B; Yang P; Fu D; Fu W; Li W; Cai L Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):231-5. PubMed ID: 24666490 [TBL] [Abstract][Full Text] [Related]
6. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335 [TBL] [Abstract][Full Text] [Related]
7. FDG-PET/CT in lymphoma. Juweid ME Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925 [TBL] [Abstract][Full Text] [Related]
8. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Newman JS; Francis IR; Kaminski MS; Wahl RL Radiology; 1994 Jan; 190(1):111-6. PubMed ID: 8259386 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT. Kim HO; Kim JS; Shin YM; Ryu JS; Lee YS; Lee SG J Nucl Med; 2010 Dec; 51(12):1849-56. PubMed ID: 21098794 [TBL] [Abstract][Full Text] [Related]
10. PET/CT for therapy response assessment in lymphoma. Hutchings M; Barrington SF J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407 [TBL] [Abstract][Full Text] [Related]
11. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study. Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212 [TBL] [Abstract][Full Text] [Related]
12. Restaging of patients with lymphoma. Comparison of low dose CT (20 mAs) with contrast enhanced diagnostic CT in combined [18F]-FDG PET/CT. la Fougère C; Pfluger T; Schneider V; Hacker M; Bröckel N; Morhard D; Hundt W; Bartenstein P; Becker C; Tiling R Nuklearmedizin; 2008; 47(1):37-42. PubMed ID: 18278211 [TBL] [Abstract][Full Text] [Related]
13. Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. Picardi M; Soricelli A; Pane F; Zeppa P; Nicolai E; De Laurentiis M; Grimaldi F; Rotoli B Radiology; 2009 May; 251(2):574-82. PubMed ID: 19401581 [TBL] [Abstract][Full Text] [Related]
14. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707 [TBL] [Abstract][Full Text] [Related]